Adneuris licenses cebranopadol to Maruishi for Japan and South Korea
Adneuris Therapeutics has signed an exclusive licence agreement with Osaka-based Maruishi Pharmaceutical, granting the Japanese company rights to develop and commercialise cebranopadol for pain in Japan and South Korea. The deal brings Adneuris a $35 million upfront payment, which includes a $10 million royalty investment tied to US sales, plus tiered double-digit royalties and additional milestone payments linked to development and commercial progress in the licensed territory.
The agreement is Adneuris' second ex-US licensing transaction, following an earlier deal covering Greater China. Cebranopadol, a wholly owned subsidiary of New Jersey-based Tris Pharma, is the parent company's lead investigational asset. Adneuris said it expects to submit a New Drug Application to the FDA later this year for the treatment of acute pain.
The candidate and its clinical profile
Cebranopadol is a dual agonist targeting both the nociceptin/orphanin FQ peptide (NOP) receptor and the mu-opioid peptide (MOP) receptor, a mechanism the company describes as first-in-class. The drug has completed Phase 3 development for moderate-to-severe acute pain and Phase 2 work across several chronic pain indications. Its two pivotal Phase 3 studies, ALLEVIATE-1 and ALLEVIATE-2, evaluated the candidate following abdominoplasty and bunionectomy respectively, together enrolling more than 2,400 participants. In both studies, cebranopadol showed statistically significant reductions in pain versus placebo over 48 hours, reduced use of opioid rescue medication, and sustained pain control, according to the company.
The FDA has granted cebranopadol Fast Track Designation for chronic low back pain. Separately, the National Institute on Drug Abuse has awarded Tris Pharma a five-year grant of up to $16.6 million to study the compound's potential in opioid use disorder and broader substance use disorders, pointing to a pipeline optionality that goes beyond the acute pain NDA.
Ketan Mehta, founder and chief executive of Tris Pharma, said Maruishi's "deep expertise in perioperative and pain management, combined with its established commercial infrastructure across Japan," made the company a natural partner for the territory.
Market and competitive context
The partnership reflects sustained out-licensing appetite for novel pain assets in the Asia-Pacific region, where regulatory agencies in Japan and South Korea have historically been receptive to differentiated analgesics, particularly those with evidence of reduced misuse potential. Japan's pain-management market is served by a relatively small number of opioid-class drugs due to regulatory and cultural constraints on opioid prescribing, which could, if cebranopadol's safety profile holds up in regulatory review, give it meaningful differentiation against conventional MOP agonists such as oxycodone.
Maruishi, founded in 1888 and focused on perioperative and pain medicines, has prior experience partnering with international biopharmaceutical firms to introduce novel compounds into the Japanese market. Its therapeutic alignment with cebranopadol's target indications reduces the commercial risk that typically accompanies deals where the licensee operates outside the relevant specialty.
More broadly, the pain-management sector is under heightened scrutiny following the opioid crisis in the United States and Canada, and regulators and payers alike are looking for analgesics that demonstrate clinical non-inferiority to standard-of-care options alongside a cleaner safety and dependence profile. The dual-NMR mechanism is positioned by Adneuris and Tris Pharma as addressing exactly that need, though the commercial case will ultimately rest on how the FDA and its counterparts in Japan and South Korea assess the full clinical dataset. The anticipated US NDA submission later this year will be a critical read-across for the programme's regional partners.
Aurora Partners advised Adneuris on the transaction.